BioSpace News Archive

Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced topline results from the Phase 2 randomized, double-blind, placebo-controlled trial (PEAK trial) evaluating AVTX-002 (anti-LIGHT mAb) in patients with poorly controlled non-eosinophilic asthma (NEA).

CollPlant Biotechnologies (NASDAQ: CLGN) today announced the achievement of a milestone with respect to the clinical phase dermal filler product, according to its agreement with AbbVie for the development of a regenerative dermal and soft tissue filler product.

Accuray Incorporated (NASDAQ: ARAY) announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000 ® Index and the broad-market Russell 3000 ® Index, which will be effective today.

POINT Biopharma Global Inc. today announced a collaboration on the development of a global 212 Pb radioisotope and radioligand supply chain and drug manufacturing network to specifically support the clinical development and commercialization of 212Pb-labeled radioligands by each company.

Eyenovia, Inc. announced that the company was added to the small cap Russell 2000® and broad market Russell 3000® Indexes.

LianBio (Nasdaq: LIAN) today announced that CAMZYOS® (mavacamten) has received marketing approval for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from the Singapore Health Sciences Authority.

Femasys Inc. announced today the approval of an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA) to evaluate the safety and efficacy of FemBloc®, a first-of-its-kind, non-surgical, non-implant, in-office solution for permanent birth control in a pivotal clinical trial (the “FINALE” trial).

BioVie Inc. today announced that baseline data from its multicenter, randomized, placebo-controlled Phase 3 study ( NCT04669028 ) of NE3107 in patients with mild to moderate Alzheimer’s Disease (AD) was presented at the American Diabetes Association Annual Meeting.

CereVasc, Inc. and LianMedical announced a partnership focused on bringing CereVasc’s eShunt® System and related products to patients and providers in China, Hong Kong, Taiwan, and Macaw.

Sorrento Therapeutics, Inc. (OTC: SRNEQ) announced today the full enrollment in a pivotal Phase 3 study of Sorrento’s oral Mpro inhibitor, Ovydso (STI-1558), in mild or moderate symptomatic adults infected with SARS-CoV-2, or COVID-19.